ANI Pharmaceuticals


Roth Capital Maintains Buy On ANI Pharmaceuticals Following 4Q:14 Update

ANI Pharmaceuticals Inc (NASDAQ:ANIP) shares are down 1.5% today after the company released fourth-quarter net earnings of $20.

ANI Pharmaceuticals: Convertible Offering Leaves A Lot Of Dry Powder, Says Oppenheimer

In a research report sent to investors today, Oppenheimer analyst Rohit Vanjani reiterated an Outperform rating on ANI Pharmaceuticals (NASDAQ:ANIP) with a $58 price …

Oppenheimer Raises ANI Pharmaceuticals Price Target Following Strong 3Q14 Results

Oppenheimer analyst Rohit Vanjani today joined the crowd, raising ANI Pharmaceuticals (NASDAQ:ANIP) price target to $55 (from $37), while maintaining an Outperform rating on the …

Roth Capital Raises ANI Pharmaceuticals Price Target Following 3Q14 Results

Roth Capital analyst Scott Henry reaffirmed a Buy rating on ANI Pharmaceuticals (NASDAQ:ANIP) and increased his price target to $55, following the company’s …

Oppenheimer Sets Expectations On ANI Pharmaceuticals Ahead Of 3Q14 Results

In a research report sent to investors Thursday, Oppenheimer analyst Rohit Vanjani assigned an Outperform rating on ANI Pharmaceuticals (NASDAQ:ANIP) with a $37 …

Roth Capital Reiterates Buy On ANI Pharmaceuticals As Shares Have Come Under Pressure

In a research report issued today, Roth Capital analyst Scott Henry reiterated a Buy rating on ANI Pharmaceuticals (NASDAQ:ANIP) with a $40 price target, as the share …

Roth Capital Reiterates Buy On Ani Pharmaceuticals Following 2Q14 Results

In research note published yesterday, Roth Capital analyst Scott Henry reiterated a Buy rating on ANI Pharmaceuticals (ANIP) with a $40 price target, …

Roth Capital Reiterates Buy On ANI Pharmaceuticals Following Vancocin Acquisition

Friday, after the close, ANI Pharmaceuticals (ANIP) announced that the company acquired US rights to the antibiotic Vancocin (125mg and 250mg capsules) from Shire (SHPG). The …

Roth Capital Maintains Buy On ANI Pharmaceuticals Ahead Of 2Q14 Results

Yesterday, Roth Capital analyst Scott Henry issued a note in which he maintained a Buy rating on ANI Pharmaceuticals (ANIP) with a $40 …

Roth Capital Maintains Buy On ANI Pharmaceutical Following The Acquistion of Lithobid

In a research note released Tuesday, Roth Capital analyst Scott Henry maintained a Buy rating on ANI Pharmaceuticals (ANIP) and raised his price target to $40.00 (from $38.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts